ACTR-10. PHASE 0 TRIAL OF CERITINIB IN BRAIN METASTASES AND RECURRENT GLIOBLASTOMA

BACKGROUND: Ceritinib is an orally bioavailable, small molecule inhibitor for ALK/IGFR1/FAK, which are highly expressed in glioblastoma and brain metastases. Preclinical and clinical reports suggest ceritinib activity in central nervous system (CNS) malignancies, yet there is no direct evidence in p...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Fiorelli, Roberto, Li, Jing, Bao, Xun, DeRogatis, Alanna, Pennington-Krygier, Chelsea, Kim, Seongho, Mehta, Shwetal, Sanai, Nader
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Adult Clinical Trials - Non-Immunologic
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847618/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.053
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires